Skip to main content
MSF.org
MSF Staff
  • English
  • العربية
  • Español
  • Français
.هذه الصفحة غير متاحة باللغة العربية
Esta página no está disponible en este idioma.
Cette page n’est pas disponible dans cette langue.
This page is not available in this language.
MSF medical guidelines
MSF medical guidelines

Main navigation

  • Home
  • Guidelines
  • Internal guidelines
  • Updates
  • Order
  • About
  • Contact
  • FAQ

All guidelines

Tuberculosis

Essential drugs

English العربية Spanish French

Clinical guidelines - Diagnosis and treatment manual

English العربية Spanish French

Essential obstetric and newborn care

English العربية French

Management of A CHOLERA EPIDEMIC

English French

Management of A MEASLES EPIDEMIC

English French

Tuberculosis

English French

Public health engineering

English French
  • Acknowledgements
  • Foreword
  • Abbreviations and acronyms
  • Chapter 1: Introduction and epidemiology
  • Chapter 2: Clinical presentation
  • Chapter 3: Diagnosis and follow-up investigations
  • Chapter 4: Diagnosis of active tuberculosis in children
  • Chapter 5: Diagnostic algorithm for pulmonary tuberculosis in symptomatic adolescents and adults
  • Chapter 6: Screening for active tuberculosis
  • Chapter 7: Case definitions
  • Chapter 8: Tuberculosis drugs and treatment regimens
  • Chapter 9: Treatment of drug-susceptible tuberculosis
  • Chapter 10: Treatment of multidrug-resistant and rifampicin-resistant tuberculosis
  • Chapter 11: Treatment of rifampicin-susceptible and isoniazid-resistant tuberculosis
  • Chapter 12: Tuberculosis and HIV co-infection
  • Chapter 13: Adherence to tuberculosis treatment
  • Chapter 14: Infection prevention and control
  • Chapter 15: Follow-up of staff exposed to tuberculosis
  • Chapter 16: Treatment of latent tuberculosis infection
  • Chapter 17: Monitoring and evaluation
  • Appendices
    • Appendix 1. Xpert assays
    • Appendix 2. Interpretation of Xpert assay results
    • Appendix 3. Collection, storage, and shipment of respiratory specimens
    • Appendix 4. Sputum smear microscopy
    • Appendix 5. Time required for diagnostic test results
    • Appendix 6. Ventilated workstation and biosafety cabinet
    • Appendix 7. Lymph node fine needle aspiration
    • Appendix 8. Protein estimation
    • Appendix 9. Tuberculin skin test
    • Appendix 10. Drug information sheets and patient instructions for active TB treatment
      • Tuberculosis drug information sheets
        • Amikacin (Am)
        • Amoxicillin/clavulanic acid ratio 4:1 (Amx/Clv)
        • Bedaquiline (Bdq)
        • Clofazimine (Cfz)
        • Cycloserine (Cs) or terizidone (Trd)
        • Delamanid (Dlm)
        • Ethambutol (E)
        • Ethionamide (Eto) or prothionamide (Pto)
        • Imipenem/cilastatin (Ipm/Cln)
        • Isoniazid - Standard dose (H)
        • Isoniazid - High dose (Hh)
        • Levofloxacin (Lfx)
        • Linezolid (Lzd)
        • Meropenem (Mpm)
        • Moxifloxacin (Mfx)
        • Para-aminosalicylate sodium (PAS)
        • Pretomanid (Pa)
        • Pyrazinamide (Z)
        • Rifabutin (Rfb)
        • Rifampicin (R)
        • Rifapentine (P)
        • Streptomycin (S)
      • Patient instructions
    • Appendix 11. TB drugs in pregnant or breastfeeding women
    • Appendix 12. Dose adjustments in renal insufficiency
    • Appendix 13. Daily dose of TB drugs using fixed-dose combinations
    • Appendix 14. Monitoring of patients on DS-TB treatment
    • Appendix 15. Monitoring of patients on DR-TB treatment
    • Appendix 16. Additional investigations in DR-TB
    • Appendix 17. Management of adverse effects
    • Appendix 18. Compassionate use of TB drugs
    • Appendix 19. Drug interactions and overlapping toxicities
    • Appendix 20. Treatment supporters
    • Appendix 21. Therapeutic patient education
    • Appendix 22. Assessment of adherence to TB treatment
    • Appendix 23. Basic tool for assessing risk of TB transmission
    • Appendix 24. Recommendations for air change per hour
    • Appendix 25. Overview of ventilation techniques
    • Appendix 26. Germicidal ultraviolet lamps
    • Appendix 27. Respirators
    • Appendix 28. Surgical masks
    • Appendix 29. BCG vaccine
    • Appendix 30. DS-TB and Hr-TB treatment card
    • Appendix 31. DS-TB and Hr-TB register
    • Appendix 32. MDR/RR-TB treatment card
    • Appendix 33. MDR/RR-TB register
    • Appendix 34. Request form for smear microscopy and Xpert assays
    • Appendix 35. Request form for culture, pDST, LPA, genome sequencing
    • Appendix 36. Drug-o-gram
    • Appendix 37. Case detection and enrolment report and treatment outcome report
    • Appendix 38. TB facility assessment sheet

Breadcrumb

  • Home
  • Tuberculosis
  • Appendices
  • Appendix 10. Drug information sheets and patient instructions for active TB treatment

Tuberculosis drug information sheets

Select language:
Enter
Permalink
Download
Comment
Return to top
On this page

     

     

    Update: November 2022

     

    • Amikacin (Am)
    • Amoxicillin/clavulanic acid ratio 4:1 (Amx/Clv)
    • Bedaquiline (Bdq)
    • Clofazimine (Cfz)
    • Cycloserine (Cs) or terizidone (Trd)
    • Delamanid (Dlm)
    • Ethambutol (E)
    • Ethionamide (Eto) or prothionamide (Pto)
    • Imipenem/cilastatin (Ipm/Cln)
    • Isoniazid - Standard dose (H)
    • Isoniazid - High dose (Hh)
    • Levofloxacin (Lfx)
    • Linezolid (Lzd)
    • Meropenem (Mpm)
    • Moxifloxacin (Mfx)
    • Para-aminosalicylate sodium (PAS)
    • Pretomanid (Pa)
    • Pyrazinamide (Z)
    • Rifabutin (Rfb)
    • Rifampicin (R)
    • Rifapentine (P)
    • Streptomycin (S)
    Path

    Book traversal links for Tuberculosis drug information sheets

    • Appendix 10. Drug information sheets and patient instructions for active TB treatment
    • Amikacin (Am)

    Send feedback about this page or ask a general question

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    MSF medical guidelines
    MSF medical guidelines
    © Médecins Sans Frontières 2025

    Footer

    • Disclaimer
    • Cookie Policy
    • Privacy Notice